Zydus and Lupin Sign Licensing Agreement for Co-Marketing Saroglitazar Mg, a Critical Treatment for Chronic Liver Diseases in India
Nov 03, 2023
Ahmedabad (Gujarat) [India], November 3: Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as "Zydus") a discovery-driven, global lifesciences company and Lupin Limited (Lupin), a global pharma major, today announced that they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces pill burden and offers greater convenience for patients.